Skip to search formSkip to main contentSkip to account menu

Response Evaluation Criteria in Solid Tumors Version 1.1

Known as: RECIST 1.1 
A standardized guideline developed by the Response Evaluation Criteria in Solid Tumors (RECIST) Working Group in 2000 and revised in 2009, which is… 
National Institutes of Health

Related topics

Related topics

1 relation
Clinical Data Interchange Standards Consortium Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
Purpose: Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of… 
Highly Cited
2019
Highly Cited
2019
Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity
PurposeRadioembolization of liver metastases of neuroendocrine neoplasms (NEN) has shown promising results; however, the current… 
Highly Cited
2018
Highly Cited
2018
Prospective observational study of 177Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol…
PurposePeptide receptor radionuclide therapy in patients with neuroendocrine tumours has yielded promising results. This… 
Highly Cited
2018
Highly Cited
2018
Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)
Highly Cited
2018
Highly Cited
2018
Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single‐arm phase 2 clinical trial
Cutaneous squamous cell carcinoma (CSCC) is a very common malignancy in which most patients present with localized disease… 
Review
2017
Review
2017
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma
The purpose of this study was to evaluate 18F-FDG PET/CT scanning as an early predictor of response to immune checkpoint… 
Highly Cited
2016
Highly Cited
2016
CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy?
Background Response Evaluation Criteria In Solid Tumors (RECIST) are known to have limitations in assessing the response of… 
Highly Cited
2014
Highly Cited
2014
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced…
INTRODUCTION Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1), may underestimate activity and does not… 
Highly Cited
2013
Highly Cited
2013
Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids
Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment so far have been… 
Highly Cited
2011
Highly Cited
2011
EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)